Results 11 to 20 of about 1,352 (137)
Advances and challenges in immunoPET methodology [PDF]
Frontiers in Nuclear MedicineImmuno-positron emission tomography (immunoPET) enables imaging of specific targets that play a role in targeted therapy and immunotherapy, such as antigens on cell membranes, targets in the disease microenvironment, or immune cells.
Philipp Mohr +6 more
doaj +4 more sources
89Zr-mAb uptake interpretation requires the use of tissue to plasma ratios corrected for antibody catabolism [PDF]
EJNMMI ResearchBackground Typically, tissue uptake, expressed in tissue over plasma ratio (TPR), is reported from a 89Zr-mAb PET study. Nonspecific antibody catabolism and the residualizing property of 89Zr hamper the use of tissue uptake as a measure for target ...
Marc C. Huisman +18 more
doaj +2 more sources
Journal for ImmunoTherapy of Cancer, 2021 Background Programmed cell death protein 1/programmed death-ligand 1 (PD-1/PD-L1) blocking antibodies including cemiplimab have generated profound clinical activity across diverse cancer types.
Gavin Thurston +14 more
doaj +1 more source
Frontiers in Immunology, 2022 IntroductionPositron emission tomography (PET) using radiolabeled Abs as imaging tracer is called immuno-PET. Immuno-PET can verify therapeutic Ab delivery and can noninvasively quantify global levels of target expression in tumors of living subjects ...
Jin Hee Lee +7 more
doaj +1 more source
Journal for ImmunoTherapy of Cancer, 2022 Purpose CD103, an integrin specifically expressed on the surface of cancer-reactive T cells, is significantly increased during successful immunotherapy across human malignancies.
Danique Giesen +9 more
doaj +1 more source
Mitigation of noise-induced bias of PET radiomic features [PDF]
, 2022 INTRODUCTION: One major challenge in PET radiomics is its sensitivity to noise. Low signal-to-noise ratio (SNR) affects not only the precision but also the accuracy of quantitative metrics extracted from the images resulting in noise-induced bias.
Boellaard, Ronald +6 more
core +1 more source
Scientific Reports, 2021 Glypican-3 (GPC3) is a tumor associated antigen expressed by hepatocellular carcinoma (HCC) cells. This preclinical study evaluated the efficacy of a theranostic platform using a GPC3-targeting antibody αGPC3 conjugated to zirconium-89 (89Zr) and yttrium-
Kevin P. Labadie +14 more
doaj +1 more source
EJNMMI Research, 2023 Background Early intrahepatic recurrence is common after surgical resection of hepatocellular carcinoma (HCC) and leads to increased morbidity and mortality.
Kevin P. Labadie +13 more
doaj +1 more source
A novel [89Zr]-anti-PD-1-PET-CT to assess response to PD-1/PD-L1 blockade in lung cancer
Frontiers in Immunology, 2023 BackgroundHarnessing the anti-tumor immune system response by targeting the program cell death protein (PD-1) and program cell death ligand protein (PD-L1) axis has been a major breakthrough in non-small cell lung cancer (NSCLC) therapy.
Ander Puyalto +36 more
doaj +1 more source
Visualizing immune checkpoints and T cells in patients with cancer [PDF]
, 2023 This thesis describes the results of clinical studies using molecular imaging to visualize immune checkpoint molecules and immune cells in patients with solid tumors.
van de Donk, Pim
core +1 more source